Posted by Michael Wonder on 29 Jan 2016
Agenda for the 3 February 2016 TC meeting
29 January 2016 - The Transparency Commission will consider the reimbursement of sufentanil (Zalviso), efmoroctocog alfa (Elocto) and asfotase alfa (Stensiq).
For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-01/ordre_du_jour_ct_03022016.pdf
